Rein Therapeutics (RNTX) Other Gross PP&E Adjustments (2016 - 2025)
Rein Therapeutics (RNTX) has disclosed Other Gross PP&E Adjustments for 10 consecutive years, with -$255000.0 as the latest value for Q3 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 69.89% to -$255000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.7 million, a 37.71% increase, with the full-year FY2024 number at -$522000.0, down 89.13% from a year prior.
- Other Gross PP&E Adjustments was -$255000.0 for Q3 2025 at Rein Therapeutics, up from -$349000.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$192000.0 in Q4 2022 to a low of -$847000.0 in Q3 2024.
- A 5-year average of -$450315.8 and a median of -$459000.0 in 2021 define the central range for Other Gross PP&E Adjustments.
- Biggest YoY gain for Other Gross PP&E Adjustments was 95.12% in 2021; the steepest drop was 534.78% in 2021.
- Rein Therapeutics' Other Gross PP&E Adjustments stood at -$200000.0 in 2021, then increased by 4.0% to -$192000.0 in 2022, then plummeted by 43.75% to -$276000.0 in 2023, then crashed by 89.13% to -$522000.0 in 2024, then skyrocketed by 51.15% to -$255000.0 in 2025.
- Per Business Quant, the three most recent readings for RNTX's Other Gross PP&E Adjustments are -$255000.0 (Q3 2025), -$349000.0 (Q2 2025), and -$574000.0 (Q1 2025).